Ascendis Pharma A/S (NASDAQ:ASND) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report released on Friday morning,Benzinga reports. The brokerage currently has a $170.00 price target on the biotechnology company’s stock.

A number of other equities research analysts have also weighed in on the stock. Stifel Nicolaus raised their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a report on Friday. StockNews.com lowered Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Tuesday. Citigroup raised their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Jefferies Financial Group upped their target price on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th. Finally, Wedbush reissued an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock traded up $2.23 during trading on Friday, reaching $126.51. 1,448,861 shares of the company’s stock were exchanged, compared to its average volume of 450,130. Ascendis Pharma A/S has a 52-week low of $90.13 and a 52-week high of $161.00. The firm has a market cap of $7.67 billion, a price-to-earnings ratio of -13.59 and a beta of 0.66. The company’s 50-day moving average is $132.30 and its two-hundred day moving average is $132.70.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. Analysts anticipate that Ascendis Pharma A/S will post -7.35 EPS for the current year.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in ASND. Signaturefd LLC increased its stake in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 80 shares during the period. Profund Advisors LLC raised its stake in shares of Ascendis Pharma A/S by 3.0% in the 2nd quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock worth $398,000 after buying an additional 85 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 143 shares during the period. Thrivent Financial for Lutherans boosted its stake in Ascendis Pharma A/S by 0.3% during the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock valued at $11,717,000 after buying an additional 228 shares in the last quarter. Finally, Avior Wealth Management LLC grew its holdings in Ascendis Pharma A/S by 3.0% during the third quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company’s stock worth $1,226,000 after acquiring an additional 240 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.